Manganese

Manganese operates mechanistically as an obligate metal cofactor or activator for a small set of enzymes critical to mitochondrial function, gluconeogenesis, urea cycle, connective tissue synthesis, and brain glutamine/glutamate handling. Its mechanism is better understood by enzyme than by tissue. At supraphysiologic exposure, the same chemistry that makes manganese useful becomes neurotoxic through basal ganglia redox dysregulation and dopaminergic disruption.

MnSOD (superoxide dismutase 2, SOD2). The mitochondrial superoxide dismutase is a 96 kDa homotetramer encoded by nuclear SOD2 on chromosome 6q25; each monomer contains one catalytic manganese ion coordinated by three histidines and one aspartate in the active site. The enzyme is synthesized as a precursor with a mitochondrial targeting sequence, imported to the mitochondrial matrix via TOM/TIM translocases, processed, and assembled with manganese insertion. The catalytic mechanism alternates manganese between Mn3+ (oxidized) and Mn2+ (reduced) states across two half-reactions: Mn3+-SOD + O2•- → Mn2+-SOD + O2 (superoxide oxidized to oxygen), then Mn2+-SOD + O2•- + 2H+ → Mn3+-SOD + H2O2 (second superoxide reduced to hydrogen peroxide). The product H2O2 is then handled by glutathione peroxidase (GPx, a selenium-dependent enzyme) or catalase to yield water and oxygen. MnSOD is the first-line defense against superoxide generated at complex I and complex III electron leak sites in the mitochondrial electron transport chain. SOD2 knockout mice die within days-weeks with severe phenotypes (cardiomyopathy, hepatic steatosis, neurodegeneration). Conditional tissue-specific SOD2 knockouts have revealed organ-specific oxidative damage phenotypes. Partial SOD2 deficiency (heterozygous, or Val16Ala rs4880 polymorphism) may contribute to disease risk in aging, cancer, diabetes, and neurodegeneration. MnSOD activity declines with age and is upregulated by mitochondrial biogenesis pathways (PGC-1α, SIRT3 deacetylation of SOD2 lysines). Caloric restriction and exercise upregulate SOD2, as do certain phytochemicals (sulforaphane via Nrf2-ARE pathway).

Arginase. The final cytosolic enzyme of the hepatic urea cycle, arginase-1 (ARG1) hydrolyzes L-arginine to L-ornithine and urea — the terminal excretory step of ammonia detoxification. Arginase contains two manganese ions per subunit (a binuclear active site) coordinated by histidine and aspartate residues that activate a bridging hydroxide for nucleophilic attack on arginine's guanidinium carbon. ARG1 deficiency is a rare inborn error of urea cycle with progressive spastic quadriplegia, seizures, and growth retardation. Extrahepatic arginase-2 (ARG2, mitochondrial, found in kidney, brain, macrophages) plays roles in polyamine synthesis, NO regulation (competing with NOS for arginine substrate), and macrophage polarization.

Pyruvate carboxylase (PC). A biotin-dependent mitochondrial matrix carboxylase converting pyruvate to oxaloacetate (anaplerosis of the TCA cycle, gluconeogenesis initiation in liver and kidney). PC is one of the biotin-using carboxylases. Manganese allosterically activates PC and binds in the active site (along with biotin and ATP). PC deficiency is an autosomal recessive inborn error with lactic acidosis, neurologic dysfunction, and variable severity.

Glutamine synthetase (GS). The brain (astrocytic) and liver enzyme converting glutamate + NH3 + ATP to glutamine + ADP + Pi — the primary ammonia-fixation reaction in the central nervous system and the mechanism by which astrocytes clear excitotoxic glutamate from the synapse. GS contains two divalent metal ions per active site (typically manganese in vertebrate GS), essential for the adenylation-dependent catalytic cycle. Astrocyte GS activity depends on manganese, and manganese accumulation in astrocytes (which preferentially take up manganese at the blood-brain barrier) may alter glutamine-glutamate cycling and contribute to the neurobehavioral manifestations of hepatic encephalopathy and manganism. Hyperammonemia and hyperglutaminergic states (hepatic encephalopathy) involve GS biology at the center.

Glycosyltransferases and proteoglycan synthesis. Several enzymes in the biosynthesis of glycosaminoglycans (chondroitin sulfate, heparan sulfate) and glycoproteins require manganese as activator — specifically the xylosyltransferases, galactosyltransferases, and glucuronosyltransferases of proteoglycan core protein modification. These activities explain the bone and cartilage defects (short long bones, disproportionate growth, ataxia) observed in manganese-deficient animal models. Human relevance is small in free-living populations but theoretically contributes to the historical rationale for manganese in bone supplementation protocols.

Neurotoxicity mechanism. At normal brain concentrations, manganese supports SOD2 in mitochondria, GS in astrocytes, and diverse metalloenzymes. At accumulation levels from occupational or TPN exposure, manganese produces progressive basal ganglia dysfunction through several mechanisms: (1) Mn3+ is a one-electron oxidant that can directly generate hydroxyl radicals from hydrogen peroxide via Fenton-like chemistry, producing oxidative damage to mitochondrial proteins and lipids; (2) manganese disrupts complex I and complex II of the electron transport chain, reducing ATP synthesis and increasing superoxide leak; (3) manganese alters dopamine synthesis and degradation (catechol-O-methyltransferase, monoamine oxidase interactions, tyrosine hydroxylase modulation) and promotes dopamine auto-oxidation with generation of reactive quinones; (4) manganese modulates α-synuclein aggregation (relevant to parkinsonian phenotype overlap); (5) manganese disrupts glutamate-glutamine cycling via GS changes and impairs astrocyte-neuron ammonia handling. The globus pallidus is preferentially affected because of high local manganese transporter density and high baseline metabolic activity. The clinical phenotype differs from idiopathic PD in important ways — pallidal rather than nigral predominance, poor L-DOPA response, dystonia more prominent than rest tremor, prominent neuropsychiatric prodrome — reflecting this different anatomic and biochemical target pattern.

Transport biology. Dietary manganese crosses the enterocyte brush border primarily via DMT1 (SLC11A2, proton-coupled divalent metal transporter, shared with iron, zinc, copper, cobalt, and lead) and ZIP8/ZIP14 (SLC39A8/SLC39A14) at lower luminal concentrations. Absorbed manganese binds α2-macroglobulin and albumin in portal blood, reaches the liver with nearly complete first-pass extraction. Hepatic manganese is transported into bile by SLC30A10 — the primary excretion route. At the blood-brain barrier, manganese crosses via DMT1 and ZIP14 on brain capillary endothelium; in brain parenchyma, manganese is taken up by astrocytes preferentially over neurons, supporting astrocytic GS and SOD2. Brain efflux of manganese is slow, producing the long biological half-life in the CNS. Cellular mitochondrial uptake occurs via the mitochondrial calcium uniporter (MCU), which transports Mn2+ with similar affinity to Ca2+; this loads mitochondrial manganese onto MnSOD (primary physiologic fate) and also makes mitochondria a major compartment for manganese accumulation in toxicity.

Iron interaction biology. Iron deficiency upregulates duodenal DMT1 and HCP1 (heme carrier protein 1) to maximize iron absorption; this concurrently increases manganese absorption via DMT1. Iron deficiency also increases brain manganese uptake by increasing DMT1 expression at the blood-brain barrier. The pediatric manganism literature includes cases in iron-deficient children with low dietary iron intake and high exposure to manganese-contaminated water or infant formula — and in populations exposed to manganese-contaminated well water, iron deficiency is a risk modifier. This makes iron status a relevant variable in manganese clinical assessment.

Hepatic excretion and cholestasis. The near-total dependence of manganese elimination on biliary excretion makes cholestatic liver disease and biliary obstruction the dominant acquired risk factors for manganese accumulation. Primary biliary cholangitis, primary sclerosing cholangitis, cirrhosis of any etiology, and cholestasis of pregnancy all reduce manganese clearance. Parenteral nutrition patients with underlying liver dysfunction are at particular risk, and their TPN manganese content should be minimized or eliminated depending on biliary flow status and serum/blood manganese levels.

Serum and whole-blood manganese measurement is the standard assessment. Normal reference ranges: serum 0.5-2.0 μg/L, whole blood 4-15 μg/L; whole blood is generally preferred for toxicity assessment because erythrocyte manganese is more stable and less subject to hepatic first-pass variability. MRI T1-weighted imaging reveals globus pallidus hyperintensity in manganese accumulation — a specific and sensitive imaging marker that normalizes over weeks to months after exposure cessation.

Manganese is an essential trace mineral and redox-active transition metal occupying a peculiar place in human nutrition: absolutely required at milligram doses for mitochondrial antioxidant defense, gluconeogenesis, urea cycle function, and connective tissue synthesis — yet potently neurotoxic at the hundredfold-higher doses encountered occupationally (welders, miners, battery workers) and in patients on long-term parenteral nutrition with inadequately controlled trace mineral content. The adult body contains approximately 10-20 mg of manganese distributed across bone (25-40%), liver, kidney, pancreas, pituitary, and brain (particularly the basal ganglia — globus pallidus, substantia nigra, caudate, putamen), with manganese concentrations in the globus pallidus being among the highest in the body and providing the anatomical substrate for manganism, the parkinsonian syndrome of chronic manganese overexposure. Carl Scheele and Johan Gottlieb Gahn isolated elemental manganese in 1774 through carbon reduction of the mineral pyrolusite (MnO2); the name derives from the Latin "magnes" reflecting the mineral's historic use in glassmaking. The essentiality of manganese for mammalian health was established through 1930s-1950s experimental deficiency studies in chicks, rats, and guinea pigs that demonstrated bone malformation, ataxia, and reproductive failure, and crystallized clinically with parenteral nutrition trace element development in the 1970s-1980s and the concurrent recognition of parenteral manganese toxicity in liver disease patients in the 1990s.

The adequate intake (AI) for manganese is 2.3 mg/day for men and 1.8 mg/day for women (Institute of Medicine 2001; there is no RDA because definitive evidence for a minimum physiologic requirement has not been established through deficiency-repletion studies in humans), with pregnancy AI of 2.0 mg/day and lactation 2.6 mg/day. The tolerable upper intake level (UL) for adults is 11 mg/day — notably, the UL sits only approximately 5x above the AI, one of the narrower safety ranges among essential nutrients, reflecting manganese neurotoxicity concerns. Dietary manganese is abundant in whole grains (particularly brown rice, oats, whole wheat, quinoa), nuts (pine nuts, hazelnuts, pecans, almonds), legumes (soybeans, chickpeas, lentils), tea (notably, a strong cup of tea can contain 0.5-1 mg manganese — tea-heavy diets readily provide sufficient manganese), leafy greens (spinach, Swiss chard, kale), pineapple, seeds (pumpkin, flax, chia), and some shellfish (mussels, oysters). Typical US dietary intake ranges 2-6 mg/day for adults, solidly within the AI range. Clinical manganese deficiency from ordinary diet is exceptionally rare; it has been described only in a handful of contrived metabolic ward studies and in highly unusual clinical scenarios. The dominant manganese clinical concern is toxicity, not deficiency.

Manganese absorption is tightly controlled — one of the body's primary defenses against its inherent neurotoxicity. Intestinal absorption is only approximately 3-5% of dietary intake under normal conditions, mediated by DMT1 (divalent metal transporter 1, the same transporter that carries iron, zinc, copper, cobalt, cadmium, and lead into enterocytes) and ZIP8/ZIP14 (SLC39A8 and SLC39A14, which have higher affinity for manganese). Iron deficiency upregulates DMT1 and increases manganese absorption — potentially contributing to manganese accumulation in iron-deficient populations. Calcium, phosphate, phytate, and fiber in the diet reduce manganese absorption by forming insoluble complexes. Absorbed manganese binds α2-macroglobulin and albumin in portal blood, reaches the liver, and is largely extracted on first pass. Hepatic manganese is excreted into bile as the primary elimination route; approximately 95% of manganese clearance occurs through biliary excretion, with only minor urinary loss. This hepatic excretion pathway is critical clinically — in cholestatic liver disease, biliary obstruction, or severe hepatic dysfunction, manganese accumulates rapidly, producing the characteristic T1-hyperintensity on brain MRI in globus pallidus (the classic "manganese brain" finding in cirrhotic patients, which can regress after liver transplantation) and contributing to hepatic encephalopathy. Patients on long-term parenteral nutrition, especially those with underlying liver disease or cholestasis, develop manganese accumulation at standard trace element supplementation doses and may require manganese removal from the TPN formulation.

Cellular manganese uptake occurs through several transporters depending on tissue and redox state. SLC39A14 (ZIP14) and SLC39A8 (ZIP8) mediate manganese uptake into hepatocytes, pancreatic acinar cells, and other tissues; SLC30A10 mediates manganese efflux from hepatocytes into bile (loss-of-function SLC30A10 mutations cause a rare autosomal recessive hypermanganesemia with dystonia and polycythemia, a Mendelian disorder of manganese detoxification first described in 2012). DMT1 handles manganese uptake across the blood-brain barrier and into neurons. Intracellularly, manganese is channeled into mitochondria via the mitochondrial calcium uniporter (MCU, which transports Ca2+ but also Mn2+ at similar affinity) where it loads into MnSOD (SOD2) — the primary physiologic fate of manganese.

MnSOD (superoxide dismutase 2, SOD2) is the mitochondrial superoxide dismutase, catalyzing the dismutation of superoxide (O2•-) to hydrogen peroxide (H2O2) in the mitochondrial matrix — the primary site of reactive oxygen species generation from electron transport chain leak. SOD2 activity critically depends on its manganese cofactor. SOD2 knockout mice die within two weeks of birth from dilated cardiomyopathy, hepatic steatosis, and neurodegeneration, demonstrating the absolute essentiality of mitochondrial ROS control. A common SOD2 polymorphism, Val16Ala (rs4880), affects mitochondrial targeting and has been associated with varying cancer, diabetes, and neurodegenerative disease risk in population studies. Age-related mitochondrial dysfunction is partly attributable to declining SOD2 activity. The oxidative stress and longevity connection makes MnSOD perhaps the single most biochemically important manganese-dependent enzyme in vertebrate physiology.

Beyond MnSOD, manganese activates or is tightly bound in several other mammalian enzymes: arginase (liver urea cycle, converting arginine to ornithine + urea — the final step of ammonia detoxification), pyruvate carboxylase (gluconeogenesis and anaplerosis, converting pyruvate to oxaloacetate using biotin as primary cofactor and manganese as allosteric), phosphoenolpyruvate carboxykinase (PEPCK-M, mitochondrial gluconeogenic enzyme), glutamine synthetase (astrocyte ammonia detoxification, converting glutamate + NH3 to glutamine — critical for brain ammonia clearance and potentially one reason manganese overload exacerbates hepatic encephalopathy), and the glycosyltransferases and prolidases involved in proteoglycan synthesis (explaining the bone and cartilage defects seen in experimental manganese deficiency). Manganese is also loosely associated with many kinases and phosphatases as alternative metal cofactor where it can substitute for magnesium.

Manganese toxicity — manganism — is a parkinsonian syndrome first described in the 1830s by James Couper in Glasgow bleach-works manganese miners and extensively characterized in the 20th century in welders, smelters, battery manufacturers, and ore processing workers. Chronic inhalation of manganese-containing dust or fume produces progressive accumulation in basal ganglia, initially with neuropsychiatric prodrome (irritability, emotional lability, aggression, insomnia, sometimes called "manganese madness" or "locura manganica"), progressing to extrapyramidal motor signs resembling Parkinson disease: bradykinesia, rigidity, postural instability, dystonia (often a characteristic "cock-walk" gait on toes with hyperextension of the spine), masked facies, micrographia. Unlike idiopathic Parkinson disease, manganism predominantly affects the globus pallidus (pallidal) rather than the substantia nigra pars compacta, the tremor is less prominent, levodopa response is poor, and brain MRI shows T1-hyperintensity in globus pallidus (free manganese is paramagnetic, shortening T1 relaxation times). The Rodier 1955 reports on manganese miner neurology and the subsequent Chilean and Brazilian occupational studies established the syndrome's dose-response relationship. Welders remain the modern epidemiologic focus; several studies have found subtle motor and cognitive deficits in chronically exposed welders below the threshold for overt manganism (Racette 2017 Neurology, among others). Methylcyclopentadienyl manganese tricarbonyl (MMT) — used as an octane-boosting gasoline additive in some countries (banned in the US in most fuel — controversy around Canadian approval) — creates environmental concerns for population-level manganese exposure, though epidemiologic data remain mixed.

Parenteral nutrition manganese toxicity parallels the occupational syndrome. Patients on TPN (particularly children, patients with cholestasis, intestinal failure, or chronic liver disease) receiving standard trace element preparations develop MRI T1-hyperintense globus pallidus and hypermanganesemia; pediatric case series in the 1990s-2000s documented the phenomenon, and current ASPEN and ESPEN guidelines recommend manganese monitoring in long-term TPN and reduced or zero manganese content in the presence of cholestasis. The Mirowitz and Westcott MRI descriptions of this in cirrhotic patients preceded its recognition in TPN patients; the biology is the same — impaired biliary manganese excretion causes accumulation regardless of the exposure source.

SLC30A10 deficiency (hypermanganesemia with dystonia 1, HMNDYT1) is a rare autosomal recessive disorder first described by Tuschl 2012 (PMID 22341972) characterized by high serum manganese, MRI globus pallidus T1-hyperintensity, early-onset generalized dystonia, polycythemia, and chronic liver disease, caused by loss-of-function mutations in the hepatic manganese efflux transporter. Chelation with EDTA and iron repletion (iron and manganese share DMT1, and iron repletion competitively reduces manganese absorption) form the mainstay of treatment. A related disorder, HMNDYT2, involves SLC39A14 (ZIP14) loss-of-function preventing hepatic manganese uptake and subsequent biliary excretion, with similar clinical presentation. These Mendelian disorders established human SLC30A10 and SLC39A14 as essential components of manganese homeostasis.

Therapeutic manganese supplementation has a limited evidence base and a narrow place in medicine. It is included in multivitamin-mineral products at typical doses of 1-2 mg (consistent with the AI). Standalone manganese supplements are marketed for bone health (based on 1990s osteoporosis studies combining manganese with copper, zinc, and calcium, Strause 1994 J Nutr, which showed bone density benefits vs. calcium alone but could not isolate the manganese contribution), connective tissue synthesis, and (unproven) hypoglycemia. Given the narrow AI-UL window, the small contribution of typical supplements to total exposure, and the rarity of deficiency from ordinary diet, manganese supplementation has no clear evidence-based indication outside of parenteral nutrition in non-cholestatic patients and documented deficiency (which essentially does not occur in free-living populations). BodyHackGuide does not recommend standalone manganese supplementation for most users; typical diets (especially those with whole grains, nuts, legumes, and tea) provide ample manganese, and over-supplementation risks cumulative neurotoxicity given manganese's long half-life and poor excretion through non-biliary routes. If a multivitamin contains 1-2 mg manganese, that is appropriate; higher doses (5-20 mg manganese-only formulations marketed for "bone" or "enzyme support") carry no demonstrated benefit and measurable theoretical risk. Users with liver disease, biliary obstruction, or on chronic PPIs/antacids (which increase gastric manganese bioavailability) should specifically avoid supplemental manganese.

Manganese cross-interactions are important. Iron and manganese share DMT1 at intestinal absorption and blood-brain barrier; iron deficiency increases manganese absorption and brain uptake. Calcium, phosphate, and phytate reduce manganese absorption. Zinc has reciprocal interaction with manganese absorption at DMT1. Biotin and pantothenic-acid share the carboxylase enzyme family with manganese-activated pyruvate carboxylase, connecting manganese to the energy metabolism chain described in the B-vitamin entries. Chronic excess manganese exposure in the context of low iron (a common combination in pediatric manganism and in certain population studies) may interact with dopamine neurochemistry through shared basal ganglia vulnerability.

BodyHackGuide's take: manganese is the trace mineral that matters most for what you should NOT take. Deficiency is essentially nonexistent in ordinary diets; toxicity from occupational exposure and parenteral nutrition is a real clinical problem; supplementation offers no demonstrated benefit for free-living adults eating a reasonable diet. If you drink tea and eat nuts, whole grains, or legumes, your manganese is covered. A multivitamin providing 1-2 mg is fine. Avoid manganese-specific supplements, "superfood greens powders" with concentrated manganese, high-dose mineral blends targeting bone (use calcium, vitamin-d3, vitamin-k2, magnesium, and boron instead), and any supplementation in the presence of known liver disease. Welders, miners, and industrial workers should minimize occupational exposure; biomonitoring and medical surveillance programs exist in most regulated jurisdictions. The unique biochemistry of manganese — essential cofactor for MnSOD mitochondrial defense, yet basal ganglia toxicant — illustrates the general rule that trace minerals have narrow therapeutic windows and that ambient diet usually lands inside those windows without supplemental assistance.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Manganese Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness

Research Credibility